Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Breast Cancer”

2,815 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 2,815 results

Large-scale testing (Phase 3)Ended earlyNCT04335006
What this trial is testing

Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 80
Testing effectiveness (Phase 2)Study completedNCT00337649
What this trial is testing

Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 27
Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Testing effectiveness (Phase 2)Study completedNCT00301899
What this trial is testing

Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab

Who this might be right for
Breast Cancer
National Institutes of Health Clinical Center (CC) 37
Early research (Phase 1)Ended earlyNCT03742349
What this trial is testing

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Who this might be right for
Triple Negative Breast Cancer (TNBC)
Novartis Pharmaceuticals 64
Testing effectiveness (Phase 2)UnknownNCT02646735
What this trial is testing

Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients

Who this might be right for
Breast Cancer
Chinese Academy of Medical Sciences 148
Testing effectiveness (Phase 2)WithdrawnNCT00678626
What this trial is testing

Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer

Who this might be right for
Breast Cancer
Pfizer
Early research (Phase 1)Ended earlyNCT01876251
What this trial is testing

A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer Metastatic
Pfizer 30
Testing effectiveness (Phase 2)Study completedNCT00526045
What this trial is testing

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Who this might be right for
Breast CancerHematologic Neoplasms
Novartis Pharmaceuticals 117
Testing effectiveness (Phase 2)Active Not RecruitingNCT04902872
What this trial is testing

Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Who this might be right for
Solid Tumor, AdultEpithelial Ovarian CancerSmall Cell Lung Carcinoma+9 more
Cybrexa Therapeutics 130
Large-scale testing (Phase 3)UnknownNCT01126138
What this trial is testing

Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)

Who this might be right for
Carcinoma, Invasive Ductal, Breast
Chinese Academy of Medical Sciences 200
Testing effectiveness (Phase 2)Ended earlyNCT00323063
What this trial is testing

Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Rutgers, The State University of New Jersey 49
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05232006
What this trial is testing

PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers

Who this might be right for
Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
Assistance Publique - Hôpitaux de Paris 12
Testing effectiveness (Phase 2)UnknownNCT00066547
What this trial is testing

Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy

Who this might be right for
Breast Cancer
Jonsson Comprehensive Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00005817
What this trial is testing

Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer

Who this might be right for
Male Breast CancerRecurrent Breast CancerStage IIIB Breast Cancer+1 more
National Cancer Institute (NCI) 42
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06595563
What this trial is testing

HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer

Who this might be right for
HER2-positive Metastatic Breast CancerHER2-positive Advanced Breast Cancer
Jules Bordet Institute 87
Testing effectiveness (Phase 2)UnknownNCT03961698
What this trial is testing

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

Who this might be right for
Breast CancerRenal Cell Carcinoma
Infinity Pharmaceuticals, Inc. 91
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07339176
What this trial is testing

Intratumoral N17350 in Advanced Solid Tumors

Who this might be right for
Neoplasms, Solid TumorBreast Neoplasms, Triple-NegativeSquamous Cell Carcinoma of Skin+4 more
Onchilles Pharma Inc 275
Testing effectiveness (Phase 2)Study completedNCT00066443
What this trial is testing

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Who this might be right for
Breast Cancer
NCIC Clinical Trials Group 93
Testing effectiveness (Phase 2)UnknownNCT01492543
What this trial is testing

Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Chinese Academy of Medical Sciences 30
Load More Results